PharmaShots | Incisive News in 3 Shots

Subscribe Now

Atsena Therapeutics

Atsena Therapeutics’ ATSN-201 Gains the US FDA’s Rare Pediatric Disease Designation for Treating Retinoschisis

Atsena Therapeutics’ ATSN-201 Gains the US FDA’s Rare Pediatric Disease Designation for Treating Retinoschisis

August 14, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us